Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Clorox Co (CLX) vs Cassava Sciences Inc (FLNA) Price & Performance

Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Clorox Co vs Cassava Sciences Inc — how do they compare? Clorox Co trades at $108.39 (market cap $13.02B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Clorox Co is far larger — about 272.7× Cassava Sciences Inc's market cap, and Clorox Co pays a 4.64% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

CLXFLNA
Market Cap
$13.02B$47.75M
Sector
Consumer StaplesHealth
52-Week High
$127.16$4.64
52-Week Low
$86.12$0.87
Enterprise Value
$18.40B-$34.93M
Dividend Yield
4.64%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Clorox Co

Clorox (CLX) trades at $105.15, down 0.43% today, with a bullish technical signal from moving averages and strong momentum indicators. Recent Q2 2026 earnings beat expectations with EPS of $1.66, though Q4 2025 missed. The company reported fiscal 2025 revenue of $7.10 billion and net income of $810 million, with a high ROE of 285.64% but elevated P/B ratio of 141.28. Dividend increased to $1.25 per share, payable August 28, 2026.

Outlook is mixed: bullish technicals and profitability contrast with analyst caution (10.34% buy ratings) and a consensus price target of $97.50 below current price. Risks include inflation pressures and competitive threats from private labels. Upside hinges on execution of cost-saving initiatives and market share recovery.

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Returns comparison

Trailing returns across standard periods

About Clorox Co

With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.

Read more on CLX

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA